Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
01/2004
01/01/2004US20040002139 Methods for making recombinant proteins using apoptosis inhibitors
01/01/2004US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides
01/01/2004US20040002092 Hybrid and single chain meganucleases and use thereof
01/01/2004US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR)
01/01/2004US20040001897 Skin vitalizing composition for external use anti-aging preparation
01/01/2004US20040001895 Combination treatment for depression and anxiety
01/01/2004US20040001835 Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
01/01/2004US20040001833 Method of treating cancer using kinase inhibitors
01/01/2004US20040001821 Topical applying kinase to eye surface
01/01/2004US20040001792 Decoloring hair and skin using ascorbic acid
12/2003
12/31/2003WO2004001068A2 Use of pp2a phosphatase modulators in the treatment of mental disorders
12/31/2003WO2004001059A2 Heterocyclic inhibitors of kinases
12/31/2003WO2004001053A1 β-GLUCAN-CONTAINING FAT COMPOSITIONS AND NOVEL MICROORGANISM PRODUCING β-GLUCAN
12/31/2003WO2004001038A1 Novel gene and protein participating in neuralization of cells or tissues and utilization thereof
12/31/2003WO2004001021A1 Pasteurisation process for microbial cells and microbial oil
12/31/2003WO2004001014A2 Osteopontin, oligodendrocytes and myelination
12/31/2003WO2004001004A2 Membrane associated tumor endothelium markers
12/31/2003WO2004000875A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
12/31/2003WO2004000869A1 Glucocorticoid receptor ligands for the treatment of metabolic disorders
12/31/2003WO2004000863A1 Produrg, medicinal utilization thereof and process for producing the same
12/31/2003WO2004000858A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
12/31/2003WO2004000849A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
12/31/2003WO2004000846A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
12/31/2003WO2004000842A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
12/31/2003WO2004000841A1 Hetero-bicyclic compounds
12/31/2003WO2004000840A2 Quinuclidine derivatives and pharmaceutical compositions containing the same
12/31/2003WO2004000839A1 Thiazole derivatives as phosphodiesterase iv inhibitors
12/31/2003WO2004000837A1 Novel benzoxazolinone derivative
12/31/2003WO2004000834A1 Novel 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same
12/31/2003WO2004000833A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
12/31/2003WO2004000831A1 Indole derivatives useful as histamine h3 antagonists
12/31/2003WO2004000830A1 Novel compounds, their use and preparation
12/31/2003WO2004000829A1 Novel process
12/31/2003WO2004000828A1 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
12/31/2003WO2004000825A1 Novel compounds
12/31/2003WO2004000822A1 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
12/31/2003WO2004000819A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
12/31/2003WO2004000816A1 Androgen receptor agonist
12/31/2003WO2004000813A1 Phenoxypyridine derivative or salt thereof
12/31/2003WO2004000808A2 N-substituted piperidine derivatives as serotonin receptor agents
12/31/2003WO2004000807A1 Cannabinoid receptor agonists
12/31/2003WO2004000801A2 Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
12/31/2003WO2004000791A1 Benzene derivative
12/31/2003WO2004000789A1 Amide linker peroxisome proliferator activated receptor modulators
12/31/2003WO2004000786A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
12/31/2003WO2004000785A2 Phenyloxyalkanonic acid derivatives as hppar activators
12/31/2003WO2004000781A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
12/31/2003WO2004000762A2 Propionic acid derivatives and their use as hppars activators
12/31/2003WO2004000368A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003WO2004000365A1 Drug transport and delivery system
12/31/2003WO2004000363A1 Process for producing sustained-release composition
12/31/2003WO2004000355A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
12/31/2003WO2004000353A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs
12/31/2003WO2004000346A1 Preventives/remedies for cancer
12/31/2003WO2004000345A1 Preventives/remedies for bone and joint diseases
12/31/2003WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
12/31/2003WO2004000326A1 Combination therapy wherein a serotonin reuptake inhibitor is used
12/31/2003WO2004000324A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/31/2003WO2004000322A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000321A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000315A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
12/31/2003WO2004000307A1 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor
12/31/2003WO2004000300A1 Cyclooxygenase-2 inhibitors
12/31/2003WO2004000299A1 Body fat degradation promoters and foods and drinks
12/31/2003WO2004000296A1 (2s)-2amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
12/31/2003WO2004000294A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003WO2004000286A1 Microcapsules for the delayed, controlled release of perindopril
12/31/2003WO2004000245A1 Promoter for uptake of basic amino acid into cell and cosmetic or drug composition
12/31/2003WO2004000237A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists
12/31/2003WO2004000230A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
12/31/2003WO2004000229A2 Treatment of human multiple myeloma by curcumin
12/31/2003WO2004000205A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
12/31/2003WO2004000197A2 Quick dissolve compositions and tablets based thereon
12/31/2003WO2003088959A3 Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
12/31/2003WO2003080021A3 Formulation comprising buprenorphine
12/31/2003WO2003075839A3 Methods of inducing terminal differentiation
12/31/2003WO2003074513A3 Indole amide derivatives and their use as glycogen phosphorylase inhibitors
12/31/2003WO2003072704A3 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/31/2003WO2003072576A3 Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
12/31/2003WO2003072055A3 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
12/31/2003WO2003065991A3 N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
12/31/2003WO2003064471A3 Gene for peripheral arterial occlusive disease
12/31/2003WO2003063758A3 Bicyclic cb2 cannabinoid receptor ligands
12/31/2003WO2003063576A3 Arylsulfonamidobenzylic compounds
12/31/2003WO2003061573A3 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
12/31/2003WO2003060475A3 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
12/31/2003WO2003059269A3 Acridone inhibitors of impdh enzyme
12/31/2003WO2003055912A3 Secreted proteins
12/31/2003WO2003052138A3 Methods of detecting modification of genetic material
12/31/2003WO2003049746A3 Combination of cytochome p450 dependent protease inhibitors
12/31/2003WO2003039344A3 Methods and compositions for correction of cardiac conduction disturbances
12/31/2003WO2003035004A9 Immunotherapy for reversing immune suppression
12/31/2003WO2003020759A9 A caspase- 8 binding protein, its preparation and use
12/31/2003WO2003006492A3 Biologically active peptides
12/31/2003WO2002078747A9 Pregabalin lactose conjugates
12/31/2003WO2002070562A3 Nuclear hormone receptor ligand binding domain
12/31/2003WO2002070068A3 Lipoxin analogs as novel inhibitors of angiogenesis
12/31/2003WO2002067971A3 Use of endostatin in the treatment of ocular neovascularization
12/31/2003WO2002060378A3 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
12/31/2003WO2002048110A3 Composition for regulating animal growth, method of manufacture and use thereof
1 ... 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 ... 1564